Skip Nav Destination
Issues
15 October 2019
-
Cover Image
Cover Image
![issue cover]()
The cover shows a markup image (generated by the HALO image analysis software) for a clear-cell renal cell carcinoma section double immunostained for PD-L1 and markers of immune cells. PD-L1(+) immune cells are labeled in dark red and PD-L1(-) immune cells are labeled in light red. For details, see the article by Flaifel and colleagues on page 6080 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
Review
Clinical Trials: Targeted Therapy
Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation
Timothy Kinsella; Howard Safran; Susan Wiersma; Thomas DiPetrillo; Andrew Schumacher; Kayla Rosati; John Vatkevich; Lawrence W. Anderson; Kimberly D. Hill; Charles Kunos; Jerry M. Collins
Clinical Trials: Immunotherapy
Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study
Suzanne Shusterman; Arlene Naranjo; Collin Van Ryn; Jaquelyn A. Hank; Marguerite T. Parisi; Barry L. Shulkin; Sabah Servaes; Wendy B. London; Hiroyuki Shimada; Jacek Gan; Steven D. Gillies; John M. Maris; Julie R. Park; Paul M. Sondel
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Anna V. Tinker; Holger W. Hirte; Diane Provencher; Marcus Butler; Heather Ritter; Dongsheng Tu; Hatem A. Azim, Jr; Paulo Paralejas; Nathalie Grenier; Shirley-Ann Hahn; Janelle Ramsahai; Lesley Seymour
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Omid Hamid; Luciana Molinero; Christopher R. Bolen; Jeffrey A. Sosman; Eva Muñoz-Couselo; Harriet M. Kluger; David F. McDermott; John D. Powderly; Indrani Sarkar; Marcus Ballinger; Marcella Fassò; Carol O'Hear; Daniel S. Chen; Priti S. Hegde; F. Stephen Hodi
Author Choice
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Frederick Lansigan; Cristiana A. Costa; Bassem I. Zaki; Stephanie P. Yen; Eric S. Winer; Helen Ryan; Darcie Findley; Sara R. Metzler; Lynn Shaw; Bonnie Toaso; Todd A. MacKenzie; Youdinghuan Chen; Anne W. Beaven
Precision Medicine and Imaging
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Abdallah Flaifel; Wanling Xie; David A. Braun; Miriam Ficial; Ziad Bakouny; Amin H. Nassar; Rebecca B. Jennings; Bernard Escudier; Daniel J. George; Robert J. Motzer; Michael J. Morris; Thomas Powles; Evelyn Wang; Ying Huang; Gordon J. Freeman; Toni K. Choueiri; Sabina Signoretti
Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study
Costanza Paoletti; Jieling Miao; Emily M. Dolce; Elizabeth P. Darga; Madeline I. Repollet; Gerald V. Doyle; Julie R. Gralow; Gabriel N. Hortobagyi; Jeffrey B. Smerage; William E. Barlow; Daniel F. Hayes
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Wenxin Xu; Maneka Puligandla; Judith Manola; Andrea J. Bullock; Daniel Tamasauskas; David F. McDermott; Michael B. Atkins; Naomi B. Haas; Keith Flaherty; Robert G. Uzzo; Janice P. Dutcher; Robert S. DiPaola; Rupal S. Bhatt
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Ahmed O. Kaseb; Nora S. Sánchez; Shiraj Sen; Robin K. Kelley; Benjamin Tan; Andrea G. Bocobo; Kian H. Lim; Reham Abdel-Wahab; Marc Uemura; Roberto Carmagnani Pestana; Wei Qiao; Lianchun Xiao; Jeffrey Morris; Hesham M. Amin; Manal M. Hassan; Asif Rashid; Kimberly C. Banks; Richard B. Lanman; AmirAli Talasaz; Kenna R. Mills-Shaw; Bhawana George; Abedul Haque; Kanwal P.S. Raghav; Robert A. Wolff; James C. Yao; Funda Meric-Bernstam; Sadakatsu Ikeda; Razelle Kurzrock
Translational Cancer Mechanisms and Therapy
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Siddhartha Devarakonda; Sumithra Sankararaman; Brett H. Herzog; Kathryn A. Gold; Saiama N. Waqar; Jeffrey P. Ward; Victoria M. Raymond; Richard B. Lanman; Aadel A. Chaudhuri; Taofeek K. Owonikoko; Bob T. Li; John T. Poirier; Charles M. Rudin; Ramaswamy Govindan; Daniel Morgensztern
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar; Bose S. Kochupurakkal; Jean-Bernard Lazaro; Zhigang C. Wang; Sangeetha Palakurthi; Paul T. Kirschmeier; Chunyu Yang; Larissa A. Sambel; Anniina Färkkilä; Elizaveta Reznichenko; Hunter D. Reavis; Connor E. Dunn; Lee Zou; Khanh T. Do; Panagiotis A. Konstantinopoulos; Ursula A. Matulonis; Joyce F. Liu; Alan D. D'Andrea; Geoffrey I. Shapiro
Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model
In Ho Song; Mun Sik Jeong; Hyo Jeong Hong; Jong Il Shin; Yong Serk Park; Sang-Keun Woo; Byung Seok Moon; Kwang Il Kim; Yong Jin Lee; Joo Hyun Kang; Tae Sup Lee
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Megan Greally; Joanne F. Chou; Walid K. Chatila; Matthew Margolis; Marinela Capanu; Jaclyn F. Hechtman; Yaelle Tuvy; Ritika Kundra; Foysal Daian; Marc Ladanyi; David P. Kelsen; David H. Ilson; Michael F. Berger; Laura H. Tang; David B. Solit; Luis A. Diaz, Jr; Nikolaus Schultz; Yelena Y. Janjigian; Geoffrey Y. Ku
Author Choice
Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity
Yichen Chen; Jun Wang; Xi Wang; Xinye Li; Jingjing Song; Juan Fang; Xiangqi Liu; Tao Liu; Dikan Wang; Qunxing Li; Shuqiong Wen; Da Ma; Juan Xia; Liqun Luo; Song Guo Zheng; Jun Cui; Gucheng Zeng; Lieping Chen; Bin Cheng; Zhi Wang
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Laetitia Marzi; Ludmila Szabova; Melanie Gordon; Zoe Weaver Ohler; Shyam K. Sharan; Michael L. Beshiri; Moudjib Etemadi; Junko Murai; Kathleen Kelly; Yves Pommier
Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection
Kenji Tatsuno; Yutaka Midorikawa; Tadatoshi Takayama; Shogo Yamamoto; Genta Nagae; Mitsuhiko Moriyama; Hayato Nakagawa; Kazuhiko Koike; Kyoji Moriya; Hiroyuki Aburatani
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
Luca Lazzari; Giorgio Corti; Gabriele Picco; Claudio Isella; Monica Montone; Pamela Arcella; Erika Durinikova; Eugenia R. Zanella; Luca Novara; Fabiane Barbosa; Andrea Cassingena; Carlotta Cancelliere; Enzo Medico; Andrea Sartore-Bianchi; Salvatore Siena; Mathew J. Garnett; Andrea Bertotti; Livio Trusolino; Federica Di Nicolantonio; Michael Linnebacher; Alberto Bardelli; Sabrina Arena
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Fabienne Lucas; Kerry A. Rogers; Bonnie K. Harrington; Alexander Pan; Lianbo Yu; Justin Breitbach; Ralf Bundschuh; Virginia M. Goettl; Zachary A. Hing; Parviz Kanga; Rose Mantel; Deepa Sampath; Lisa L. Smith; Ronni Wasmuth; Danielle K. White; Pearlly Yan; John C. Byrd; Rosa Lapalombella; Jennifer A. Woyach
Advertisement
